

Ref. No.: NLL/CS/2026- 686

May 30, 2026

To,

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Symbol: NECLIFE

Scrip Code: 532649

Sub: Audited Financial Results for the Financial Year ("FY") 2025- 26 and Outcome of Board Meeting

Ref.: Regulation 30 and 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations").

Dear Sir/ Madam,

We wish to inform you that the Board of Directors of the Company, at its meeting held on Saturday, May 30, 2026, inter alia, considered and approved the following matters:

1. Audited Financial Results:

Pursuant to Regulation 33 of the LODR Regulations, the following documents are enclosed:

- Audited Standalone and Consolidated Financial Results for the quarter and FY ended March 31, 2026;
- Auditors' Reports thereon;
- Statement of Assets and Liabilities (Standalone and Consolidated) as at March 31, 2026;
- Cash Flow Statements (Standalone and Consolidated) for the FY ended March 31, 2026; and
- Declaration regarding unmodified opinion in the Auditors' Reports.

2. The proposal for re-appointment of Dr. Kuldip Kumar Bhasin (DIN: 09250008) as an Independent Director for a second consecutive term of five years with effect from September 21, 2026, subject to approval of the members at the forthcoming Annual General Meeting ("AGM").

3. The proposal for re-appointment of Dr. Indu Pal Kaur (DIN: 09686862) as an Independent Director for a second term of five years with effect from August 02, 2027, subject to approval of the members at the forthcoming AGM.

4. With reference to the Company's earlier disclosure vide letter no. NLL/CS/2026-659 dated March 02, 2026, the withdrawal of the proposal for appointment of Alankit Assignments Limited as the Registrar and Transfer Agent ("RTA") of the Company. Accordingly, KFin Technologies Limited shall continue as the existing RTA of the Company.

The disclosures as required under the LODR Regulations read with SEBI Master Circular No.

HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as amended from time to time, are enclosed as **Annexure A**.

5. Amendments to the following policies to align them with the amended provisions of the LODR Regulations:
- Materiality of Information Policy;
 - Related Party Transaction Policy; and
 - Code of Conduct for Prevention of Insider Trading

The updated policies have been uploaded on the Company's website at <https://www.necLife.com/about-3-5>.

Further, pursuant to Regulation 30(5) of the LODR Regulations and the Materiality of Information Policy, the following Key Managerial Personnel ("KMP") have been authorized:

For determining materiality of events/information:

- Mr. Sushil Kapoor, Whole Time Director & Chief Financial Officer ("CFO")
Email: sushil Kapoor@necLife.com
or in his absence, Chairman & Managing Director ("CMD") of the Company.

For making disclosures to the Stock Exchanges:

- Mr. Sanjaymohan Singh Rawat, Compliance Officer ("CO")
Email: cs@necLife.com
or in his/ her absence, the Company Secretary (if other than CO) or CFO of the Company:

The contact address for the above officials is:

Nectar Lifesciences Limited
SCO 38-39, Sector 9-D,
Chandigarh – 160009
Tel.: +91-172-5047916

The Board meeting commenced at 12:30 P.M. IST and concluded at 02:20 P.M. IST.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer



Independent Auditor's Report on the Quarterly and Year to date Audited Standalone Financial Results of NECTAR LIFESCIENCES LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of,
Nectar Lifesciences Limited,

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying Statement of Standalone Financial Results of **Nectar Lifesciences Limited ("the Company")** (hereinafter referred to as "the Statement") for the quarter and year ended 31st March, 2026 and the year to date results for the period from 1st April, 2025 to 31st March, 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these standalone financial results:

- a. are presented in accordance with the requirements of regulation 33 of the Listing Regulations in this regard; and
- b. gives a true and fair view in conformity with the recognition and measurement principle laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") read with relevant rules issued there under and other Accounting Principles generally accepted in India, of the net profit, other comprehensive Income and other financial information of the Company for the quarter and year ended 31st March 2026.

Basis for opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with



the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Companies Act, 2013 and the rules there under, and we have fulfilled our ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Standalone Financial Results.

Emphasis of Matter

We draw attention to Note No. 9 to the accompanying financial results regarding the Company's assessment of going concern basis of accounting.

We draw attention to Note No. 10 to the accompanying financial results regarding significant transactions/events undertaken during the year including slump sale and other consequential financial impacts on the Group. These events and transactions are significant to the understanding of the standalone financial results for the year ended March 31, 2026.

We draw attention to Note No. 12 to the accompanying financial results. The company has incurred substantial loss on investments.

Our opinion is not modified in respect of these matters.

Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year-to-date audited standalone financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Director is responsible for preparation and presentation of these financial results that gives true and fair view of the net profit and other comprehensive Income of the company and other financial information in accordance with the applicable Indian accounting standards prescribed under section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone financial results, whether due to fraud or error; design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Board of Directors.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The statement includes results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the listing Regulations.

For Deepak Jindal & Co.
Chartered Accountants
(Firm Regn. No. 023023N)

(Deepak Jindal)
Partner
(Membership No. 514745)
UDIN: 26514745RVHXM8079

Place: Chandigarh
Date: 30th May 2026



Independent Auditors' Report on the Quarterly and Year to Date Audited Consolidated Financial Results of the Company Pursuant to the Regulations 33 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
Nectar Lifesciences Limited (Holding Company)
Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Nectar Lifesciences Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the quarter and year ended March 31, 2026 ("the statements"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the audited financial statements of the wholly owned subsidiary "Avensis Exports Private Limited" and unaudited financial statements of the wholly owned subsidiary "Neclife PT, Unipessoal LDA", the aforesaid consolidated financial results:

- (i) include the annual financial results of the following wholly owned subsidiaries
 - a. Neclife PT, Unipessoal LDA (Inoperative)
 - b. Avensis Exports Private Limited
- (ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (iii) give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditors' Responsibilities for the Audit of the Consolidated Financial*



Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to Note No. 9 to the accompanying financial results regarding the Company's assessment of going concern basis of accounting.

We draw attention to Note No. 10 to the accompanying financial results regarding significant transactions/events undertaken during the year including slump sale and other consequential financial impacts on the Group. These events and transactions are significant to the understanding of the standalone financial results for the year ended March 31, 2026.


We draw attention to Note No. 12 to the accompanying financial results. The company has incurred substantial loss on investments.

Our opinion is not modified in respect of these matters.

Management's Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associates and jointly controlled entities in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and jointly controlled entities and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.



In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for assessing the ability of the Group and its associates and jointly controlled entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.


The respective Board of Directors of the companies included in the Group and of its associates and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associates and jointly controlled entities.

Auditors' Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If



we conclude that a material uncertainty exists, we are required to draw attention in our Auditors' report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors' report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and jointly controlled entities to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which are unaudited results certified by the board of directors of those companies, for such unaudited results, board of directors remain responsible for those results. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

We have not audited the financial statements of the wholly owned subsidiary namely Neclife PT, Unipessoal LDA-Portugal. We have relied on the unaudited financial statements of this wholly owned subsidiary namely Neclife PT, Unipessoal LDA-Portugal for the Year ended March 31, 2026, which have been incorporated in the consolidated financial statements. The annual financial statement of subsidiary reflects total assets of ₹0.02 million as at March 31, 2026 (Previous year ₹0.02 million), total revenues of "Nil" (Previous year "Nil") and net cash outflows amounting to "Nil" for the year ended on that date (Previous year "Nil"). These annual financial statements, as approved by the Board of Directors of the subsidiary companies, have been furnished to us by the



management, and our report, in so far as it relates to the amounts included in respect of the subsidiaries, is based solely on such approved financial statements. However, the size of the subsidiaries is insignificant.

The statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.



Place: Chandigarh
Date: 30th May 2026

Partner
(M. No. 514745)
UDIN: 26514745CAGZQU8545

NECTAR LIFESCIENCES LIMITED



Regd. Office: Shop No. 5, SL Enclave, Behind Sohi HP Gas Agency, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab 140507, Tel. +91-0172-5078200, 5001687, Email : cs@necLife.com, Website : www.necLife.com, [CIN: L21000PB1995PLC016664]

Statement of Standalone Financial Results for the Quarter and Year ended 31.03.2026 (₹ in Lakhs unless stated otherwise)

S. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
		Audited	Restated Unaudited	Restated Audited	Audited	Restated Audited
	Continuing Operations					
I	Income from Operations					
	Sales	-	-	-	-	-
	Less: GST Recovered	-	-	-	-	-
	Revenue from Operations	-	-	-	-	-
	Other operating Income	128.97	-	0.63	201.05	2.50
II	Other Income	629.03	66.08	17.71	728.04	185.28
III	Total Income (I + II)	758.00	66.08	18.34	929.09	187.78
IV	Expenses					
	(a) Cost of Materials consumed	-	-	-	-	-
	(b) Purchase of Stock in Trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefits expense	125.36	60.95	2.02	190.36	8.48
	(e) Finance costs	590.05	3,022.46	-	3,612.52	-
	(f) Depreciation and amortisation expense	8.28	6.19	30.01	34.26	61.81
	(g) Other expenses	5,726.27	131.52	2.62	5,878.94	10.28
	Total Expenses (IV)	6,449.96	3,221.12	34.65	9,716.08	80.57
V	Profit/(Loss) before exceptional items and tax from continuing operations (III- IV)	(5,691.96)	(3,155.04)	(16.31)	(8,786.99)	107.21
VI	Exceptional item	-	-	-	-	-
VII	Profit/(Loss) before from continuing operations (V- VI)	(5,691.96)	(3,155.04)	(16.31)	(8,786.99)	107.21
VIII	Tax Expense of continuing operations					
	Current Tax	-	-	-	-	-
	Deferred Tax	(1,971.36)	(1,102.49)	(5.71)	(3,052.88)	37.46
IX	Profit for the period from continuing operations (VII-VIII)	(3,720.60)	(2,052.55)	(10.60)	(5,734.11)	69.75
	Discontinued Operations					
	Profit before tax from discontinued operations	(7,320.58)	(9,657.26)	(18,750.17)	(53,765.51)	(16,260.60)
	Exceptional item (Gain on slump sale)	-	16,337.32	-	16,337.32	-
	Tax expenses of discontinued operations	(4,249.38)	3,200.55	(5,751.87)	(13,873.82)	(4,822.78)
	Profit for the period from discontinued operations	(3,071.20)	3,479.51	(12,998.30)	(23,554.37)	(11,437.82)
	Total Profit for the period	(6,791.80)	1,426.96	(13,008.90)	(29,288.48)	(11,368.07)
	Other Comprehensive Income					
	Items that will not be reclassified subsequently to profit or loss					
	Remeasurement of the net defined benefit liability/asset	12.18	-	82.98	12.18	82.98
	Income Tax relating to items that will not be reclassified to profit or loss	(4.26)	-	(29.00)	(4.26)	(29.00)
	Items that will be reclassified subsequently to profit or loss					
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-
	Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income, (Net of Tax)	7.92	-	53.98	7.92	53.98
	Total Comprehensive Income for the period	(6,783.88)	1,426.96	(12,954.92)	(29,280.56)	(11,314.09)
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up) (before and after exceptional item)					
	a) Basic continuing operations (In Rs.)	(1.85)	(0.92)	(0.00)	(2.62)	0.03
	b) Diluted continuing operations (In Rs.)	(1.85)	(0.92)	(0.00)	(2.62)	0.03
	c) Basic discontinued operations (In Rs.)	(1.53)	1.55	(5.80)	(10.78)	(5.10)
	d) Diluted discontinued operations (In Rs.)	(1.53)	1.55	(5.80)	(10.78)	(5.10)
	e) Basic continuing & discontinued operations (In Rs.)	(3.38)	0.64	(5.80)	(13.40)	(5.07)
	f) Diluted continuing & discontinued operations (In Rs.)	(3.38)	0.64	(5.80)	(13.40)	(5.07)

Statement of Consolidated Financial Results for the Quarter and Year ended 31.03.2026 (₹ in Lakhs unless stated otherwise)

S. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
		Audited	Restated Unaudited	Restated Audited	Audited	Restated Audited
I	Continuing Operations					
	Income from Operations					
	Sales	-	-	-	-	-
	Less: GST Recovered	-	-	-	-	-
	Revenue from Operations	-	-	-	-	-
	Other operating Income	128.97	-	0.62	201.05	2.50
II	Other Income	629.03	66.08	17.71	728.04	185.28
III	Total Income (I + II)	758.00	66.08	18.33	929.09	187.78
IV	Expenses					
	(a) Cost of Materials consumed	-	-	-	-	-
	(b) Purchase of Stock in Trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefits expense	126.22	60.95	2.02	191.22	8.48
	(e) Finance costs	590.05	3,022.46	-	3,612.52	-
	(f) Depreciation and amortisation expense	8.28	6.19	30.01	34.26	61.81
	(g) Other expenses	5,726.31	131.52	2.62	5,878.98	10.28
	Total Expenses (IV)	6,450.86	3,221.12	34.65	9,716.98	80.57
V	Profit/(Loss) before exceptional items and tax from continuing operations (III- IV)	(5,692.86)	(3,155.04)	(16.32)	(8,787.89)	107.21
VI	Exceptional item	-	-	-	-	-
VII	Profit/(Loss) before from continuing operations (V- VI)	(5,692.86)	(3,155.04)	(16.32)	(8,787.89)	107.21
VIII	Tax Expense of continuing operations					
	Current Tax	-	-	-	-	-
	Deferred Tax	(1,971.64)	(1,102.49)	(5.71)	(3,053.16)	37.46
IX	Profit for the period from continuing operations (VII-VIII)	(3,721.22)	(2,052.55)	(10.61)	(5,734.73)	69.75
	Discontinued Operations					
	Profit before tax from discontinued operations	(7,320.58)	(9,657.26)	(18,750.17)	(53,765.51)	(16,260.60)
	Exceptional item (Gain on slump sale)	-	16,337.32	-	16,337.32	-
	Tax expenses of discontinued operations	(4,249.38)	3,200.55	(5,751.87)	(13,873.82)	(4,822.78)
	Profit for the period from discontinued operations	(3,071.20)	3,479.51	(12,998.30)	(23,554.37)	(11,437.82)
	Total Profit for the period	(6,792.42)	1,426.96	(13,008.91)	(29,289.10)	(11,368.07)
	Other Comprehensive Income					
	Items that will not be reclassified subsequently to profit or loss					
	Remeasurement of the net defined benefit liability/asset	12.18	-	82.98	12.18	82.98
	Income Tax relating to items that will not be reclassified to profit or loss	(4.26)	-	(29.00)	(4.26)	(29.00)
	Items that will be reclassified subsequently to profit or loss					
	Foreign Exchange Translation Reserve (Net of Tax)	0.02	-	-	0.03	-
	Income Tax relating to items that will be reclassified to profit or loss	(0.01)	-	-	(0.01)	-
	Total Other Comprehensive Income, (Net of Tax)	7.93	-	53.98	7.94	53.98
	Total Comprehensive Income for the period	(6,784.49)	1,426.96	(12,954.93)	(29,281.16)	(11,314.09)
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up) (before and after exceptional item)					
	a) Basic continuing operations (In Rs.)	(1.85)	(0.92)	-	(2.62)	0.03
	b) Diluted continuing operations (In Rs.)	(1.85)	(0.92)	-	(2.62)	0.03
	c) Basic discontinued operations (In Rs.)	(1.53)	1.55	(5.80)	(10.78)	(5.10)
	d) Diluted discontinued operations (In Rs.)	(1.53)	1.55	(5.80)	(10.78)	(5.10)
	e) Basic continuing & discontinued operations (In Rs.)	(3.38)	0.64	(5.80)	(13.40)	(5.07)
	f) Diluted continuing & discontinued operations (In Rs.)	(3.38)	0.64	(5.80)	(13.40)	(5.07)

Notes

1. The above financial results were reviewed by Audit Committee on May 30, 2026, and approved by the Board of Directors ("Board") in its meeting held on May 30, 2026, and Audited by the Statutory Auditors of the Company. The auditor's reports are attached along with these results. The Board hereby declares that audit reports do not contain any modified opinion.
2. The Company is exclusively in the pharmaceutical business segment.
3. The Statement of Assets and Liability is attached as **Annexure 1**.
4. The Statement of Cash Flow is attached as **Annexure 2**.
5. Previous period's figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
6. The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figure in respect of the full financial year ended March 31 and the unaudited published year to date figures upto the third quarter ended December 31 which was subject to limited review.
7. The Company has two wholly owned subsidiaries with the following details: -
 - a) Neclife PT, Unipessoal LDA, remained inoperative during the year ended March 31, 2026.
 - b) Avenis Exports Private Limited ("AEPL"), which was acquired effective March 6, 2026.
8. The Company is "**Not a Large Corporate**" as per the framework provided in the SEBI Circular dated October 19, 2023 on Fund raising by issuance of debt securities by Large Entities.
9. **Going Concern**

During the year, the Company sold a substantial part of its existing business operations by way of slump sale and incurred losses. The transaction has resulted in significant liquidity, and the Company, after discharging all its debts, continues to possess adequate cash and liquid resources to meet its obligations, if any. Further, the Company has amended its object clause to undertake activities in the real estate sector and is currently evaluating the various projects under the revised business framework. In furtherance of this objective, the Company has also acquired AEPL as its wholly owned subsidiary. Considering the Company's solvent financial position and availability of funds, the Board believes that the Company will continue to operate as a going concern for the foreseeable future. Accordingly, the financial results have been prepared on a going concern basis.

10. Material Transactions

A. Discontinued Operations

a. Pharma Business

Pursuant to the Business Transfer Agreement (“BTA”) dated July 7, 2025, the Company transferred its Active Pharmaceutical Ingredients business located at Unit 1 and Unit 2, Derabassi, Punjab, and its Formulation business located at Unit 6, Baddi, Himachal Pradesh (collectively referred to as the “Pharma Businesses”) to Ceph Lifesciences Private Limited (“Ceph”) on a going concern basis through a slump sale, which was completed on November 10, 2025. The transaction was undertaken for an aggregate consideration of ₹127,000.00 lakhs, which, after adjustments for working capital in accordance with the BTA, was finalized at a consolidated consideration of ₹125,398.55 lakhs.

Out of the above amount, the Company has received ₹118,798.55 lakhs up to March 31, 2026, and the balance of ₹6,600.00 lakhs is receivable as at the year end. A resultant profit of ₹16,337.33 lakhs arising from the sale of the Pharma Businesses has been recognised under Exceptional Items.

b. Menthol Assets

Pursuant to the Asset Purchase Agreement (“APA”) dated July 7, 2025, the Company transferred the assets relating to its menthol business (“Menthol Assets”) to Ceph on November 10, 2025, for a consideration of ₹2,000.00 lakhs, and received the entire consideration.

B. Assets Classified as Held for Sale

a. Capsule Business (EHGC)

The Company has entered into a Business Transfer Agreement (“Capsule BTA”) dated December 20, 2025, with Capnest Health Care Private Limited (“Capnest”) for the slump sale of its Empty Hard Gelatin Capsule business located at Village Bhatoli Kalan, Pargana Dharpur, Tehsil Baddi, District Solan, Himachal Pradesh (“Capsule Business”), on a going concern basis, for a consideration of ₹1,990.00 lakhs, including transfer of related receivables and payables/creditors, subject to working capital adjustments specified in the Capsule BTA and approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA.

b. Other Assets

The Company is also evaluating the monetization of the following assets with the objective of optimizing non-core assets and further strengthening its liquidity position:

- (i) **Jammu Unit:** Fixed assets pertaining to the Company’s Jammu unit, which has remained inoperative. Necessary steps in relation to the proposed transaction have been initiated.

- (ii) **Land near Garhshankar, Punjab:** Vacant land situated near Garhshankar, Punjab. A portion of the said land has already been sold subsequent to the financial year end, indicating progress in the Company's planned disposal strategy.

Accordingly, the results relating to the above disposed businesses/assets have been disclosed as discontinued operations in accordance with Ind AS 105.

Further, in the audited standalone financial results, the net results of "Pharma Businesses", "Menthol Assets" and "Capsule Business" has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule III to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the year ended March 31, 2026, pertains to its continuing operations only and for that purpose the results for the other reporting periods i.e., December 31, 2025, and March 31, 2026, have been restated accordingly.

Standalone Operations relating to the "Pharma Businesses", "Menthol Assets" and "Capsule Business" in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below:

₹ in lakhs

S. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-26	31-Dec-25	31-Mar-25	31-Mar-26	31-Mar-25
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue from operations	571.35	2,173.55	42,890.76	40,138.43	1,66,997.36
2	Other income	0.18	1,214.40	168.13	1,221.82	311.38
3	Total expenses	7,892.12	13,045.21	61,809.06	95,125.77	1,83,569.34
4	Profit before tax	(7,320.58)	(9,657.26)	(18,750.17)	(53,765.51)	(16,260.60)
5	Exceptional item (Gain on slump sale)	-	16,337.32	-	16,337.32	-
6	Tax expenses	(4,249.38)	3,200.55	(5,751.87)	(13,873.82)	(4,822.78)
7	Net profit after tax	(3,071.20)	3,479.51	(12,998.30)	(23,554.37)	(11,437.82)

11. Buy-back of Equity Shares

Based on the Board's approval at its meeting held on December 03, 2025, the Company undertook a buy-back of up to 3,00,00,000 fully paid-up equity shares of ₹1 each at ₹27.00 per share, aggregating ₹8,100.00 lakhs, representing approximately 13.38% of the Company's paid-up equity share capital as at March 31, 2025, through the tender offer route on a proportionate basis from eligible equity shareholders, excluding the Promoters and Promoter Group, in accordance with Sections 68, 69 and 70 of the Companies Act, 2013 ("Act") and the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended.

The buy-back was open from December 31, 2025 to January 06, 2026. The consideration was paid by the Company on January 13, 2026, and the 3,00,00,000 equity shares were extinguished by the National Securities Depository Limited on January 20, 2026. Consequent to the buy-back, the paid-up equity share capital of the Company was reduced by ₹300.00 lakhs, with the premium of ₹7,800.00 lakhs adjusted against the Securities Premium Account and ₹300.00 lakhs transferred to the Capital Redemption Reserve in accordance with Section 69 of the Companies Act, 2013.

12. Pursuant to the approvals granted by the Board, the Company deployed certain surplus funds in mutual fund, ETF and equity instruments during the year. Subsequently, volatility in the financial markets arising from prevailing market conditions and geopolitical developments adversely impacted the value of such investments, resulting in a loss of ₹5,209.53 lakhs. The resultant impact has been recognized in the Statement of Profit and Loss in accordance with Ind AS 109 – Financial Instruments.
13. Extraordinary and Exceptional items – Refer Note 10.

**By Order of the Board of Directors
of Nectar Lifesciences Limited**

**Date: 30.05.2026
Place: Chandigarh**

**(Sanjiv Goyal)
Chairman & Managing Director**

Annexure 1

Audited Statement of Assets and Liabilities

(Rs. in Lakhs)

Sr.	Particulars	(Rs. in Lakhs)			
		Standalone		Consolidated	
		As at 31-Mar-26	As at 31-Mar-25	As at 31-Mar-26	As at 31-Mar-25
	Assets				
1	Non-current assets				
	Property, plant and equipment	344.71	57,660.46	10,340.49	57,660.46
	Capital work-in-progress	-	5,672.83	-	5,672.83
	Investment property	-	-	-	-
	Goodwill	-	-	111.24	-
	Other intangible assets	-	5,650.43	-	5,650.43
	Intangible assets under development	-	-	-	-
	Biological assets other than bearer plants	-	-	-	-
	Inventories	-	5,061.27	-	5,061.27
	Investments accounted for using equity method	-	-	-	-
	Non-current investments	49.28	24.31	23.51	23.51
	Trade receivables, non-current	-	848.71	-	848.71
	Loans, non-current	9,800.00	-	7.00	-
	Other non-current financial assets	16.03	325.12	292.84	325.12
	Deferred tax assets (net)	22,426.60	5,504.15	22,447.76	5,504.10
	Other non-current assets	55.58	217.35	55.58	217.35
	Total non-current assets	32,692.20	80,964.63	33,278.42	80,963.78
2	Current assets				
	Inventories	29.82	69,015.96	29.82	69,015.96
	Current investments	1,297.08	52.95	1,297.08	52.95
	Trade receivables, current	-	34,548.47	-	34,548.47
	Cash and cash equivalents	10,813.04	1,921.97	11,213.48	1,922.16
	Bank balance other than cash and cash equivalents	-	-	-	-
	Loans, current	9.13	85.69	9.13	85.69
	Other current financial assets	6,599.99	751.22	6,599.99	751.22
	Current tax assets (net)	-	-	-	-
	Other current assets	6,207.75	17,382.24	6,147.33	17,382.24
	Total current assets	24,956.81	123,758.50	25,296.83	123,758.69
3	Non-current assets classified as held for sale	3,585.39	-	3,585.39	-
4	Regulatory deferral account debit balances and related deferred tax Assets	-	-	-	-
	Total assets	61,234.40	204,723.13	62,160.64	204,722.47
	Equity and liabilities				
1	Equity				
	Equity attributable to owners of parent				
	Equity share capital	1,942.61	2,242.61	1,942.61	2,242.61
	Other equity	56,288.19	93,368.73	56,286.93	93,368.07
	Total equity attributable to owners of parent	58,230.80	95,611.34	58,229.54	95,610.68
	Non controlling interest	-	-	-	-
	Total equity	58,230.80	95,611.34	58,229.54	95,610.68
2	Liabilities				
	Non-current liabilities				
	Non-current financial liabilities				
	Borrowings, non-current	-	6,012.73	-	6,012.73
	Lease liabilities	-	-	-	-
	Trade payables, non-current	-	-	-	-
	(A) total outstanding dues of micro enterprises and small enterprises;	-	-	-	-
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises	-	-	-	-
	Other non-current financial liabilities	-	-	919.17	-
	Provisions, non-current	0.49	872.84	0.49	872.84
	Deferred tax liabilities (net)	-	-	-	-
	Deferred government grants, Non-current	-	-	-	-
	Other non-current liabilities	-	72.08	-	72.08
	Total non-current liabilities	0.49	6,957.65	919.66	6,957.65
	Current liabilities				
	Current financial liabilities				
	Borrowings, current	-	52,189.54	-	52,189.54
	Lease liabilities	-	-	-	-
	Trade payables, current	-	-	-	-
	(A) total outstanding dues of micro enterprises and small enterprises;	-	875.54	-	875.54
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises	-	42,936.08	-	42,936.08
	Other current financial liabilities	2,569.61	4,977.27	2,571.23	4,977.27
	Other current liabilities	26.37	883.50	33.08	883.50
	Provisions, current	0.71	292.21	0.71	292.21
	Current tax liabilities (Net)	-	-	-	-
	Deferred government grants, Current	-	-	-	-
	Total current liabilities	2,596.69	102,154.14	2,605.02	102,154.14
3	Liabilities directly associated with assets in disposal group classified as held for sale	406.42	-	406.42	-
4	Regulatory deferral account credit balances and related deferred tax liability	-	-	-	-
	Total liabilities	3,003.60	109,111.79	3,931.10	109,111.79
	Total equity and liabilities	61,234.40	204,723.13	62,160.64	204,722.47

Annexure 2

Audited Cash Flow Statement**(Rs. in Lakhs)**

PARTICULARS	Standalone		Consolidated	
	Year ended		Year ended	
	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25
CASH FLOW FROM OPERATING ACTIVITIES				
Net profit before tax from continuing operations	(8,786.99)	107.20	(8,787.89)	107.20
Net Profit before tax from discontinued operations	(70,102.83)	(16,260.60)	(70,102.83)	(16,260.60)
Adjustments For :				
Depreciation & Amortization	2,280.31	6,238.94	2,280.31	6,238.94
Exceptional loss/(gain)	16,337.32	-	16,337.32	-
Other Comprehensive Income (Net)	12.18	82.98	12.21	82.98
Provision for Doubtful debts/ Insurance Claims	(986.71)	160.81	(986.71)	160.81
Provision for Employees Retirement Benefits	(1,163.86)	149.22	(1,163.86)	149.22
Loss/ (Profit) on Sale & Restatement of Investments	5,209.53	(3.47)	5,209.53	(3.47)
Loss/ (Profit) on Sale of Fixed assets	(1,149.90)	1.42	(1,149.90)	1.42
Interest on Borrowings	3,612.52	7,457.83	3,612.52	7,457.83
Other Non-Operating Income	(728.04)	(185.61)	(728.04)	(185.61)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	(55,466.47)	(2,251.28)	(55,467.34)	(2,251.28)
Adjustments For (Increase)/decrease in Operating assets:				
Inventories	23,292.44	14,632.09	23,292.44	14,632.09
Trade receivables	31,595.47	3,347.58	31,595.47	3,347.58
Other financial assets	(5,665.18)	(40.86)	(5,665.18)	(40.86)
Other current assets	11,159.78	(877.93)	11,220.20	(877.93)
Loans	(9,723.44)	6.67	79.88	6.67
Other non-current assets	161.77	(5.57)	161.77	(5.57)
Adjustments For Increase/(decrease) in Operating Liabilities:				
Trade payables	(34,170.37)	1,845.51	(34,170.37)	1,845.51
Other financial liabilities	(2,083.18)	1,104.23	(5,037.60)	1,104.23
Other current liabilities	(763.99)	(814.15)	(809.64)	(814.14)
Other non current liabilities	(72.08)	(2.50)	(72.08)	(2.50)
CASH GENERATED FROM OPERATIONS	(41,735.25)	16,943.79	(34,872.45)	16,943.80
Direct Taxes Paid	-	-	-	-
NET CASH FLOW FROM OPERATING ACTIVITIES (A)	(41,735.25)	16,943.79	(34,872.45)	16,943.80
CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Fixed Assets	(1,152.56)	(4,379.48)	(1,227.42)	(4,379.48)
Purchase of Investments	(39,919.85)	-	(39,894.89)	-
Sale of Fixed Assets	2,045.76	0.83	2,045.76	0.83
Sale of Investments	33,441.16	-	33,441.16	-
Cash acquired on acquisition of subsidiary, (net of consideration paid)			323.69	-
Proceeds from slump sale of Pharma business	125,398.55	-	125,398.55	-
Interest Received	703.98	148.94	703.98	148.94
Dividend Received	0.04	-	0.04	-
Maturity of Insurance Policies	24.02	36.67	24.02	36.67
NET CASH USED IN INVESTING ACTIVITIES (B)	120,541.10	(4,193.04)	120,814.89	(4,193.04)
CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds/(Repayment) from Term Loans from Banks	(12,817.48)	(8,127.78)	(12,817.48)	(8,127.78)
Proceeds/(Repayment) from Working Capital Limits from Banks	(44,021.52)	2,799.71	(44,021.52)	2,799.71
Proceeds from Directors/Relatives/Entities in which directors have significant influence	(1,300.00)	-	(1,300.00)	-
Proceeds/(Repayment) of loan from other parties			(6,736.34)	-
Proceeds/(Repayment) from Vehicle Loans	(63.26)	(23.30)	(63.26)	(23.30)
Buy-back of shares	(8,100.00)	-	(8,100.00)	-
Interest Paid	(3,612.52)	(7,457.83)	(3,612.52)	(7,457.83)
NET CASH GENERATED FROM FINANCING ACTIVITIES (C)	(69,914.78)	(12,809.20)	(76,651.12)	(12,809.20)
NET INCREASE/(DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	8,891.07	(58.45)	9,291.32	(58.44)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	1,921.97	1,980.42	1,922.16	1,980.60
CASH & CASH EQUIVALENTS AT THE CLOSE OF THE YEAR	10,813.04	1,921.97	11,213.48	1,922.16

Ref: No. NLL/CS/2026- 685

Date: 30-05-2026

To,

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Declaration in term of Regulation 33(3)(d) of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations").

Dear Sirs/ Madams,

In term of the second proviso to Regulation 33(3)(d) of LODR Regulations, as amended, we hereby declare and confirm that the Statutory Auditors of the Company have not given any modified Opinion in their both Auditor's Reports for the financial year ended March 31, 2026, on:

1. the Standalone Audited Financial Results of the Company; and
2. the Consolidated Audited Financial Results of the Company.

Thanking you,

Yours faithfully,
For **Nectar Lifesciences Limited**



(Sushil Kapoor)

Chief Financial Officer

Annexure A

Sr. No.	Particulars	Disclosures
1.	Reason for appointment or discontinuation	Continuation with the old RTA, KFIN.
2.	Date on which above would become effective	May 30, 2026